Sunday, March 26, 2017 10:34:26 PM
Quote:
Drug: Brilacidin
Oral Rinse used 3 times daily for 7 weeks
The treatment time frame is just 7 weeks
The Primary Outcome is the prevention of grade 3 or 4 oral mucositis during the 7 week treatment time frame.
Quote:
Primary Outcome Measures:
Incidence of ulcerative and severe oral mucositis (WHO Grade ≥3) [ Time Frame: 7 weeks ]
Incidence of ulcerative and severe oral mucositis, defined as grade 3 or 4 on the WHO Oral Mucositis score, experienced during radiation therapy by patients with head and neck cancer receiving a cumulative radiation dose of at least 55 Gy. The WHO Score will be assessed by trained site personnel twice-weekly.
Incidence of Treatment-Emergent Adverse Events [ Time Frame: 11 weeks ]
Reporting of Adverse Events and severity of adverse events
Quote:
Cellceutix’s goal is to show that Brilacidin-OM has dual functionality in not only shortening the duration and severity of OM, but also preventing the onset of the condition, something no other drug developer has been able to achieve.
http://www.cellceutix.com/press-release/2017/1/4/cellceutix-to-present-at-biotech-showcase-2017-brilacidin-for-oral-mucositis-nears-interim-results
Preventing the incidence of grade 3 or 4 oral mucositis is not easy. Most subjects with head or neck cancer treated with RT (radiation therapy) develop grade 3 or 4 oral mucositis. See the graph below.
Quote:
Cellceutix’s goal is to show that Brilacidin-OM has dual functionality in not only shortening the duration and severity of OM, but also preventing the onset of the condition, something no other drug developer has been able to achieve.
Quote:
Secondary Outcome Measures:
Duration of ulcerative and severe oral mucositis (WHO Grade ≥3) [ Time Frame: 11 weeks ]
Duration of ulcerative and severe oral mucositis (WHO Grade ≥3) experienced by patients with head and neck cancer receiving a cumulative radiation dose of at least 55 Gy.
Duration of ulcerative oral mucositis (WHO Grade ≥2) [ Time Frame: 11 weeks ]
Duration of ulcerative oral mucositis (WHO Grade ≥2) experienced by patients with head and neck cancer receiving a cumulative radiation dose of at least 55 Gy.
Exploratory: Incidence of Mouth and Throat Soreness [ Time Frame: 11 weeks ]
Mouth and throat soreness will be assessed daily using Oral Mucositis Daily Questionnaire (OMDQ) Question #2
Exploratory: Use of Gastrostomy tube (G-tube) [ Time Frame: 11 weeks ]
Use of gastrostomy tube (G-tube) for nutritional support due to OM
Exploratory: Number of Unplanned Office Visits [ Time Frame: 11 weeks ]
Number of Unplanned Office visits, emergency department visits, and hospital admissions due to OM
Exploratory: Incidence of Unplanned Delays in Chemotherapy and/or RT Schedule [ Time Frame: 11 weeks ]
Incidence of Unplanned Delays in Chemotherapy and/or RT Schedule due to OM
Exploratory: Analgesic Concumption [ Time Frame: 11 weeks ]
Analgesic consumption for pain due to OM
Exploratory: Quality of Life (QOL) Assessment [ Time Frame: 11 weeks ]
Quality of Life assessed weekly (FACT-H&N)
The Secondary Outcomes are related to treatment with Brilacidin and the duration of the any grade of oral mucositis and quality of life benefits during the 7 weeks of treatment and 4 weeks after the 7 weeks of treatment with Brilacidin.
The addition of 4 weeks after the 7 weeks of treatment is to see if the benefits from the 7 weeks of Brilacidin treatment extend for at least another 4 weeks after the treatment ends.
Goo luck and GOD bless,
George
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM